Success Metrics

Clinical Success Rate

83.3%

Based on 30 completed trials

Completion Rate

83%(30/36)

Active Trials

4(9%)

Results Posted

57%(17 trials)

Terminated

6(13%)

Phase Distribution

Ph phase_3

11%

Ph early_phase_1

Ph phase_4

27%

Ph phase_1

13%

Ph not_applicable

11%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution45 total trials

Early Phase 1First-in-human

2(4.4%)

Phase 1Safety & dosage

6(13.3%)

Phase 2Efficacy & side effects

15(33.3%)

Phase 3Large-scale testing

5(11.1%)

Phase 4Post-market surveillance

12(26.7%)

N/ANon-phased studies

5(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.9%

30 of 38 finished

Non-Completion Rate

21.1%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(30)

Terminated(8)

Other(2)

Detailed Status

Completed30

Terminated6

Active, not recruiting2

Recruiting2

unknown2

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (4.4%)

Phase 16 (13.3%)

Phase 215 (33.3%)

Phase 35 (11.1%)

Phase 412 (26.7%)

N/A5 (11.1%)

Trials by Status

active_not_recruiting24%

recruiting24%

unknown24%

terminated613%

withdrawn24%

not_yet_recruiting12%

completed3067%

Recent Activity

4 active trials

Showing 5 of 45

recruitingphase_4

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

NCT01821690

View all 45 trials

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more

NCT04400266Phase 4

Buspirone and Melatonin for Depression Following Traumatic Brain Injury

Recruiting

NCT05511909Phase 2

Evaluating Buspirone to Treat Opioid Withdrawal

Recruiting

NCT04105114Early Phase 1

Transformation of Paralysis to Stepping

Active Not Recruiting

NCT07439042Phase 4

Buspirone for Anxiety in Autistic Youth

Not Yet Recruiting

NCT01821690Phase 4

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Completed

NCT02313194Phase 1

Spinal Cord Neuromodulation for Spinal Cord Injury

Active Not Recruiting

NCT05041322Phase 2

Improving Ventilatory Capacity in Those With Chronic High Level SCI

Completed

NCT01850355Not Applicable

An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Completed

NCT04807517Phase 4

Buspirone Treatment of Anxiety in Williams Syndrome

Completed

NCT03432065Phase 2

A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders

Withdrawn

NCT01395953Phase 2

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Withdrawn

NCT04052776Phase 1

Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Completed

NCT03587142Phase 2

Buspirone for Early Satiety and Symptoms of Gastroparesis

Completed

NCT02617017Phase 3

Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease

Completed

NCT05430217Phase 3

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Completed

NCT05377619Phase 1

Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial

Completed

NCT01496612Phase 2

Buspirone Therapy for Localized Epilepsy

Terminated

NCT02458469Phase 2

Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

Completed

NCT03538431Phase 4

Improving Driving in Young People With Autism Spectrum Disorders

Completed

NCT02589340Phase 1

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 45